Przejdź do zawartości
Merck

Novel 2-(2-(4-aryloxybenzylidene) hydrazinyl)benzothiazole derivatives as anti-tubercular agents.

Bioorganic & medicinal chemistry letters (2011-11-15)
Vikas N Telvekar, Vinod Kumar Bairwa, Kalpana Satardekar, Anirudh Bellubi
ABSTRAKT

A series of structurally novel, substituted 2-(2-(4-aryloxybenzylidene) hydrazinyl)benzothiazole derivatives incorporating 2-hydrazinyl benzothiazole and 4-(aryloxy)benzaldehyde were designed and synthesized using molecular hybridization approach. All the synthesized compounds exhibited promising activity (MIC 1.5-29.00μg/ml) against Mycobacteriumtuberculosis H37Rv strains of using REMA. Five of the evaluated compounds exhibit MIC <3.0μg/ml. Compound (E)-6-chloro-2-(2-(4-(2,4-dichlorophenoxy)benzylidene)hydrazinyl) benzothiazole showed MIC of 1.5μg/ml. Thus, this compound could act as a potential lead for further development of new anti-tubercular drugs.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Isoniazid, analytical standard, ≥99% (TLC)
Sigma-Aldrich
4-Phenoxybenzaldehyde, 98%